Pharmaceutical

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.

May 25, 2024 - 04:00
ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.
Read the original article

Tags:

Previous Article

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

Next Article

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Suicides and homicides among young Americans jumped early in the pandemic, study says

Suicides and homicides among young Americans jumped ear...

Jun 16, 2023

Sutro strengthens its immuno-oncology pipeline with two new ADCs

Sutro strengthens its immuno-oncology pipeline with two...

Aug 12, 2023

A new study of sick infants sees potential in DNA sequencing, but also a need for better ways to interpret the genome

A new study of sick infants sees potential in DNA seque...

Jul 12, 2023